Literature DB >> 17494017

Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes.

Scott M Grundy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17494017      PMCID： PMC1867899          DOI： 10.1136/bmj.39202.399942.AD

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

1.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.

Authors:  Sidney C Smith; Jerilyn Allen; Steven N Blair; Robert O Bonow; Lawrence M Brass; Gregg C Fonarow; Scott M Grundy; Loren Hiratzka; Daniel Jones; Harlan M Krumholz; Lori Mosca; Richard C Pasternak; Thomas Pearson; Marc A Pfeffer; Kathryn A Taubert
Journal:  Circulation       Date:  2006-05-16       Impact factor: 29.690

2.  Are lipid-lowering guidelines evidence-based?

Authors:  J Abramson; J M Wright
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

3.  Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth.

Authors:  H C McGill; C A McMahan; G T Malcom; M C Oalmann; J P Strong
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-01       Impact factor: 8.311

4.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

Authors:  J C LaRosa; J He; S Vupputuri
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

5.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

6.  Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.

Authors:  F M Sacks; A M Tonkin; J Shepherd; E Braunwald; S Cobbe; C M Hawkins; A Keech; C Packard; J Simes; R Byington; C D Furberg
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

7.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
View more
  4 in total

Review 1.  Cardiovascular disease and primary ovarian insufficiency.

Authors:  Melissa Wellons
Journal:  Semin Reprod Med       Date:  2011-10-03       Impact factor: 1.303

2.  Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.

Authors:  Quynh A Truong; Sabina A Murphy; Carolyn H McCabe; Annemarie Armani; Christopher P Cannon
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-04-12

3.  Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.

Authors:  Samia Mora; Robert J Glynn; Judith Hsia; Jean G MacFadyen; Jacques Genest; Paul M Ridker
Journal:  Circulation       Date:  2010-02-22       Impact factor: 29.690

4.  Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.

Authors:  Beth L Abramson; Pascale Benlian; Mary E Hanson; Jianxin Lin; Arvind Shah; Andrew M Tershakovec
Journal:  Lipids Health Dis       Date:  2011-08-22       Impact factor: 3.876
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.